Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | PRKCA | P17252 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24620400 | 0.85 | JAK2 (0.36) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL279200 | 0.80 | SYK (0.39) | ADORA2AADORA1 | |
| SCHEMBL16454353 | 0.79 | JAK2 (0.43) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL31440273 | 0.78 | JAK2 (0.42) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL28587194 | 0.78 | JAK2 (0.42) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL2625468 | 0.75 | ADRB1 (0.41) | — | |
| SCHEMBL27269565 | 0.75 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL19670056 | 0.75 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL24965477 | 0.75 | ADORA2A (0.36) | ADORA2AADORA1 | |
| SCHEMBL12553829 | 0.75 | IDH1 (0.33) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20160159781-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159781-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | JAK2 1416/4885ROCK2 1204/4885PRKCQ 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.